Lytone's patented strain LT12 debuted its multifunctional uric acid-lowering results research at the 19th International Symposium on Probiotics and Health

From May 22 to 24, 2024, the 19th International Symposium on Probiotics and Health (ISPH) hosted by the China Society for Food Science and Technology was successfully held in Guangzhou. Focusing on probiotics and cutting-edge health technologies, Lytone Enterprise Inc. debuted LT-12 the patented Lactobacillus paracasei strain and its latest research results, including information on uric acid management, intestinal health and kidney protection. Dr. Tina Tseng, chief operating officer and technical director of the R&D department of Shanghai Lytone Biochemicals, LTD., attended the seminar and shared the multifunctional uric acid-lowering mechanism of LT12, which attracted great attention from the scene.

https://mp.weixin.qq.com/s/_KGgjKuVs5frntKyq5Ph5g